iTeos Therapeutics (NASDAQ:ITOS) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies. Headquartered in Boston, Massachusetts, and with research facilities in Belgium, iTeos aims to address unmet needs in cancer treatment by modulating key pathways in the tumor microenvironment. The company applies its expertise in adenosine biology and amino acid deprivation to develop first-in-class and best-in-class candidates designed to enhance antitumor immune responses.
The company’s most advanced program, EOS-448, is an antibody targeting TIGIT, an immune checkpoint receptor, with the potential to restore T-cell activity and improve clinical outcomes for patients with solid tumors. In addition to EOS-448, iTeos is advancing EOS-850, a small-molecule inhibitor of A2A adenosine receptor signaling, and a preclinical pipeline that includes arginase and IDO pathway modulators. Each candidate is being evaluated both as monotherapy and in combination with established checkpoint inhibitors and other oncology agents, reflecting iTeos’s commitment to developing versatile treatment regimens.
Founded in 2017 as a spin-out from the de Duve Institute in Belgium, iTeos has rapidly grown through a series of strategic collaborations and financing rounds. The company maintains partnerships with leading academic institutions and pharmaceutical companies to accelerate the translation of its scientific discoveries into clinical candidates. iTeos’s global presence enables the execution of multi-center clinical trials across North America, Europe and Asia, ensuring broad patient access and diverse data collection.
iTeos is led by a seasoned management team with extensive experience in oncology drug development, clinical operations and regulatory affairs. The board of directors includes industry veterans who have guided companies from early discovery through approval and commercialization. Leveraging its robust scientific platform and collaborative approach, iTeos Therapeutics is positioned to advance its pipeline and deliver innovative treatments that may transform outcomes for cancer patients worldwide.
